Liver Cirrhosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 126 pages | ID: L876CFBA0C45EN
VPAResearch

Abstracts

2020 Liver Cirrhosis PIPELINE HIGHLIGHTS
Liver Cirrhosis is one of the widely researched conditions during 2020 with 26 companies actively focusing on realizing pipeline’s potential. Development of Liver Cirrhosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Liver Cirrhosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Liver Cirrhosis.

Good progress is anticipated during 2020 and 2021 with Liver Cirrhosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Liver Cirrhosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Liver Cirrhosis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Liver Cirrhosis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Liver Cirrhosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Liver Cirrhosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Liver Cirrhosis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Liver Cirrhosis DRUG PROFILES
Liver Cirrhosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Liver Cirrhosis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Liver Cirrhosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Liver Cirrhosis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 26 Liver Cirrhosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Liver Cirrhosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Advantagene Inc, BIOCND Inc, Bristol-Myers Squibb, Conatus Pharmaceuticals Inc, D&D Pharmatech Co Ltd, Elixirgen Therapeutics LLC, Galectin Therapeutics Inc, Gilead Sciences Inc, Grifols SA, Gwo Xi Stem Cell Applied Technology Co Ltd, Hepion Pharmaceuticals Inc, International Stem Cell Corp, INVENT Pharmaceuticals Inc, Laekna Therapeutics Shanghai Co Ltd, LBL Biotech Corp, Mina Therapeutics Ltd, NGM Biopharmaceuticals Inc, Oncocross Co Ltd, Pharmicell Co Ltd, PRISM Pharma Co Ltd, Promethera Biosciences SA, Rohto Pharmaceutical Co Ltd, SCM lifescience Co Ltd, Versantis AG, VESSL Therapeutics Ltd, Xfibra Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Liver Cirrhosis
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO LIVER CIRRHOSIS

1.1 Liver Cirrhosis- Disease overview
1.2 Liver Cirrhosis- Market Size
1.3 Liver Cirrhosis- Companies Involved

2. LIVER CIRRHOSIS PIPELINE SNAPSHOT- 2020

2.1 Liver Cirrhosis Pipeline by Phase
2.2 Liver Cirrhosis Pipeline by Mechanism of Action
2.3 Liver Cirrhosis Pipeline by Route of Administration
2.4 Liver Cirrhosis Pipeline- New Molecular Entities
2.5 Liver Cirrhosis Pipeline- Orphan Drug Designation/ Special Designation

3. LIVER CIRRHOSIS DRUG PROFILES

3.1 Current Status
3.2 Liver Cirrhosis Drug Snapshot
3.3 Liver Cirrhosis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Advantagene Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.2 BIOCND Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.3 Bristol-Myers Squibb Liver Cirrhosis Pipeline Insights and Clinical Trials
4.4 Conatus Pharmaceuticals Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.5 D&D Pharmatech Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.6 Elixirgen Therapeutics LLC Liver Cirrhosis Pipeline Insights and Clinical Trials
4.7 Galectin Therapeutics Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.8 Gilead Sciences Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.9 Grifols SA Liver Cirrhosis Pipeline Insights and Clinical Trials
4.10 Gwo Xi Stem Cell Applied Technology Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.11 Hepion Pharmaceuticals Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.12 International Stem Cell Corp Liver Cirrhosis Pipeline Insights and Clinical Trials
4.13 INVENT Pharmaceuticals Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.14 Laekna Therapeutics Shanghai Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.15 LBL Biotech Corp Liver Cirrhosis Pipeline Insights and Clinical Trials
4.16 Mina Therapeutics Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.17 NGM Biopharmaceuticals Inc Liver Cirrhosis Pipeline Insights and Clinical Trials
4.18 Oncocross Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.19 Pharmicell Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.20 PRISM Pharma Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.21 Promethera Biosciences SA Liver Cirrhosis Pipeline Insights and Clinical Trials
4.22 Rohto Pharmaceutical Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.23 SCM lifescience Co Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.24 Versantis AG Liver Cirrhosis Pipeline Insights and Clinical Trials
4.25 VESSL Therapeutics Ltd Liver Cirrhosis Pipeline Insights and Clinical Trials
4.26 Xfibra Inc Liver Cirrhosis Pipeline Insights and Clinical Trials

5. LIVER CIRRHOSIS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information